X4 Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
X4 Pharmaceuticals has a total shareholder equity of $22.9M and total debt of $75.6M, which brings its debt-to-equity ratio to 329.6%. Its total assets and total liabilities are $130.0M and $107.1M respectively.
Key information
329.62%
Debt to equity ratio
US$75.63m
Debt
| Interest coverage ratio | n/a |
| Cash | US$86.95m |
| Equity | US$22.94m |
| Total liabilities | US$107.07m |
| Total assets | US$130.01m |
Recent financial health updates
Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?
Apr 19Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?
Oct 07Recent updates
US Launch And EMA Approval Will Expand Global Reach
The transition to a commercial-stage pharmaceutical and strategic international partnerships could significantly boost revenue growth and international market presence.X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
Jul 02Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Mar 26Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?
Apr 19Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?
Oct 07X4 Pharmaceuticals: Upcoming Catalysts
Sep 19X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%
Jul 20X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended
Jul 01X4 Pharma: Late Stage Nanocap Targeting Rare Diseases
Aug 03Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?
Jun 22Financial Position Analysis
Short Term Liabilities: XFOR's short term assets ($95.7M) exceed its short term liabilities ($25.9M).
Long Term Liabilities: XFOR's short term assets ($95.7M) exceed its long term liabilities ($81.2M).
Debt to Equity History and Analysis
Debt Level: XFOR has more cash than its total debt.
Reducing Debt: XFOR's debt to equity ratio has increased from 21.3% to 329.6% over the past 5 years.
Debt Coverage: XFOR's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if XFOR's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/08 22:37 |
| End of Day Share Price | 2025/07/08 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
X4 Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| Arlinda Lee | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |